NCT05852405 (ID-ALS) is a clinical trial in Motor Neuron Disease, Amyotrophic Lateral Sclerosis, sponsored by Ambulanzpartner Soziotechnologie APST GmbH.

Who is sponsoring NCT05852405?

NCT05852405 is sponsored by Ambulanzpartner Soziotechnologie APST GmbH.

What condition does NCT05852405 study?

NCT05852405 studies Motor Neuron Disease, Amyotrophic Lateral Sclerosis.

Is NCT05852405 still recruiting?

NCT05852405 is currently completed. Last updated 29 January 2025.

Last reviewed 2025-01-29 · How we verify

NCT05852405: ID-ALS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Characteristics, Natural History, Health Care Measures, and Genetic Screening in Patients With ALS

Completed Last updated 29 January 2025

What this trial tests

trial in Motor Neuron Disease, Amyotrophic Lateral Sclerosis in 2,000 participants. Completed in 31 December 2024.

Timeline

1 August 2021

Primary endpoint
31 December 2024

31 December 2024

Quick facts

Lead sponsor	Ambulanzpartner Soziotechnologie APST GmbH
Status	Completed
Study type	OBSERVATIONAL
Enrollment	2,000
Start date	1 August 2021
Primary completion	31 December 2024
Estimated completion	31 December 2024
Sites	1 location across Germany

Conditions studied

Motor Neuron Disease, Amyotrophic Lateral Sclerosis — all drugs for Motor Neuron Disease, Amyotrophic Lateral Sclerosis →

Sponsor

Ambulanzpartner Soziotechnologie APST GmbH

Who can join

18 and older, any sex, with Motor Neuron Disease, Amyotrophic Lateral Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients with sporadic ALS (sALS), which refers to those without a family history of ALS, are typically not subjected to genetic investigations as part of their standard care. Therefore, their mutation status is often unknown. Even patients with familial ALS (fALS), who have a known family history of ALS, are not regularly screened for genetic mutations. This project aims to study a large group of ALS patients, examining their family history, clinical characteristics, healthcare measures, and genetic variants in ALS's most commonly mutated genes: SOD1, C9orf72, FUS, and TARDBP. Examining genetically distinct ALS cohorts is significant, as understanding the relationship between genotype and disease progression is essential in determining the therapeutic potential of future genetic therapies.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Motor Neuron Disease, Amyotrophic Lateral Sclerosis

Currently open trials in the same condition.

NCT07187388 — Investigating the Impact of Electrical Stimulation on Facial Pain, Jaw Movement and Oral Health in People With Motor Neu · NA · recruiting
NCT06885918 — ALS Research Collaborative · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05852405 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ambulanzpartner Soziotechnologie APST GmbH
Last refreshed: 29 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05852405.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing